Brief: ADC Therapeutics Says Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals
22/09/2022 24:06
Sept 21 (Reuters) - ADC Therapeutics SA ADCT.N :
* INITIAL SAFETY RUN‐IN RESULTS FROM LOTIS-5 PHASE 3 TRIAL
DEMONSTRATE ORR OF 75% AND 40% CR RATE WITH NO NEW SAFETY
SIGNALS
* CAMI PIVOTAL PHASE 2 DATA TO BE HIGHLIGHTED IN ENCORE ORAL
AND
POSTER PRESENTATIONS
Source text for Eikon: ID:nBw4vH1wTa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview